Page 70 - Read Online

Page 6 of 8 Lee et al. Hepatoma Res 2020;6:21 I http://dx.doi.org/10.20517/2394-5079.2019.44

carcinoma. J Hepatol 2014;61:S79-90.
13. Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Transl Hepatol
2018;6:79-84.
14. Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C
infection and hepatocellular carcinoma: expert review. Gastroenterology 2019;156:2149-57.
15. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, et al. A sustained virological response to interferon or interferon/ribavirin reduces
hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicenter study in Taiwan. Antivir Ther
2006;11:985-94.
16. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related
morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-8,288.e1.
17. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on
the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013;58:495-501.
18. Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C
patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 2015;60:573-81.
19. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of
hepatocellular carcinoma: a meta-analysis of observational studies. Ann Inter Med 2013;158:329-37.
20. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Association between sustained virological response and all-cause
mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
21. Janjua NZ, Chong M, Kuo M, Woods R, Wong J, et al. Long-term effect of sustained virological response on hepatocellular carcinoma
in patients with hepatitis C in Canada. J Hepatol 2017;66:504-13.
22. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans
with hepatitis C virus infection. Hepatology 2016;64:130-7.
23. Chung RT, Baumert TF. Curing chronic hepatitis C-the arc of a medical triumph. N Engl J Med 2014;370:1576-8.
24. McGlynn EA, Adams JL, Kramer J, Sahota AK, Silverberg MJ, et al. Assessing the safety of direct-acting antiviral agents for hepatitis
C. JAMA Network Open 2019;2:e194765.
25. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing,
managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org [Last accessed on 14 Apr 2020]
26. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631-40.
27. Wyles DL, Sulkowski MS, Dieterich D. Management of hepatitis C/HIV coinfection in the era of highly effective hepatitis C virus
direct-acting antiviral therapy. Clin Infect Dis 2016;63 Suppl 1:S3-11.
28. Kohli A, Alshati A, Georgie F, Manch R, Gish RG. Direct-acting antivirals for the treatment of chronic hepatitis C in patients with
chronic kidney disease. Therap Adv Gastroenterol 2016;9:887-97.
29. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, et al. Oral direct-acting agent therapy for hepatitis C virus
infection: a systematic review. Ann Intern Med 2017;166:637-48.
30. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, et al. Outcomes after successful direct-acting antiviral therapy for
patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.
31. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, et al. Eradication of hepatitis C virus infection in patients with cirrhosis
reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142-6.
32. Su F, Ioannou GN. Hepatocellular carcinoma risk after direct-acting antiviral therapy. Clin Liver Dis (Hoboken) 2019;13:6-12.
33. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-
acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
34. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular
carcinoma. J Hepatol 2017. Epub ahead of print. doi: 10.1016/j.jhep.2017.08.030.
35. Piñero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, et al. Treatment with direct-acting antivirals for HCV decreases but
does not eliminate the risk of hepatocellular carcinoma. Liver Int 2019;39:1033-43.
36. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a
multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21.
37. Lazo M, Nwankwo C, Daya NR, Thomas DL, Mehta SH, et al. Confluence of epidemics of hepatitis C, diabetes, obesity, and chronic
kidney disease in the United States Population. Clin Gastroenterol Hepatol 2017;15:1957-64.
38. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV
therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
39. Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, et al. Direct-acting antiviral treatment for hepatitis C virus infection and
risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018;47:1278-87.
40. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-
related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
41. Cabibbo G, Celsa C, Cammà C, Craxì A. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating
cancer? Liver Int 2018;38:2108-16.
42. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic
patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
43. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol
2016;65:663-5.
44. Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, et al. Time association between HCV therapy and hepatocellular carcinoma
emergence in patients with cirrhosis. The relevance of non-characterized nodules. J Hepatol 2019;70:874-84.